Please login to the form below

Not currently logged in
Email:
Password:

Former Sanofi SVP to chair Idera

James Geraghty joins the firm with 20 years biotech experience from Genzyme

James Geraghty, IderaIdera Pharmaceuticals has named James Geraghty as the company's new chairman.

Idera specialises in developing toll-like receptors (TLRs) for autoimmune and inflammatory conditions and will benefit from Geraghty's extensive career in the life sciences industry, which includes 20 years ion senior roles at leading biotech Genzyme.

He was later appointed senior VP, North America strategy at Sanofi after the company took over Genzyme in 2011, before leaving earlier this year to become entrepreneur-in-residence at venture capital firm Third Rock Ventures.

“I believe that the addition of Jim and his extensive experience comes at an ideal moment, and we look forward to his guidance and contributions as we advance our programmes toward later stage development,” said Dr Sudhir Agrawal, CEO of Idera.

These programmes involve the company's TLR antagonist drug candidates, which Idera says have shown proof-of-concept in clinical trials and are set for further studies in psoriasis and other conditions.

19th July 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics